Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC
Kairos Pharma has reported interim safety results from its ongoing Phase I clinical trial of ENV-105 (carotuximab), along with AstraZeneca's …
-
Smith+Nephew unveils Lynx Coblation Laryngeal Wand for laryngology
Smith+Nephew has commercially launched its Lynx Coblation Laryngeal Wand, a device developed for ear, nose and throat (ENT) surgeons carrying …
-
Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy
Harbour BioMed and Kelun-Biotech have received approval from China’s National Medical Products Administration (NMPA) for their investigational new drug (IND) …
-
Sound Pharmaceuticals concludes subject enrolment for SPI-1005 trial
Sound Pharmaceuticals has concluded subject enrolment for its second Phase III clinical trial assessing SPI-1005 in adults with probable or …
-
Neuraptive secures exclusive licence from Washington University for nerve device
Neuraptive Therapeutics has secured an exclusive licence from Washington University in St Louis for a bioresorbable wireless electronic stimulation device …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Innovent licenses IBI355 rights to Spero for up to $1.1bn
Innovent Biologics has agreed an exclusive licence deal worth up to $1.1bn with Spero Therapeutics, granting Spero the rights to …
-
Claria Medical secures FDA De Novo classification for hysterectomy device
Claria Medical has secured De Novo classification and marketing authorisation from the US Food and Drug Administration (FDA) for its …
-
First participant dosed in Ionis’ Phase I-II ASCEND study
Ionis Pharmaceuticals has dosed the first participant in its Phase I-II ASCEND trial evaluating ION337, an investigational ribonucleic acid (RNA)-targeted …
-
Cellares and Sonoma partner to automate cell therapy manufacturing
Cellares and Sonoma Biotherapeutics have entered a collaboration to automate the manufacturing of the latter’s lead cell therapy programme, SBT-77-7101, …
-
Virax Biolabs enters immune profiling product supply deal with Fosun
Virax Biolabs Group subsidiary Virax Biolabs (UK) has signed an exclusive commercial supply agreement with Fosun Diagnostics for its research-use-only …
-
Novo Nordisk reports Phase III FRONTIER4 study results for denecimig
Novo Nordisk has reported positive results from the ongoing Phase III FRONTIER4 extension trial, assessing the long-term safety and efficacy …
-
FDA approves MSD’s Keytruda combinations for MIBC
The US Food and Drug Administration (FDA) has approved two of Merck & Co’s (MSD) Keytruda (pembrolizumab) and Keytruda Qlex …
-
TRiCares begins US IDE pivotal trial of TTVR system
TRiCares SAS has enrolled and treated the first patient in its TRICURE US IDE pivotal study of the Topaz transcatheter …
-
FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial
Quoin Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application …
-
Apertura and NIH institutes to test gene therapy for NPC1
Apertura has entered a cooperative research and development agreement (CRADA) with various NIH institutes for a gene therapy to treat …
